Comparison of Sorafenib and DEB-TACE in patients wth hepatocellular carcinoma refractory to conventional TACE.
Not Applicable
- Conditions
- hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000014999
- Lead Sponsor
- Musashino Red Cross Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patiets that written agreement of participation for this study was not obtained. 2)Patients whose HCC with invasion of stem of portal vein. 3)Patients with uncontrollable ascites. 4)Patients whose TMN stage of HCC is IVb. 5)Patients whose Child-Pugh is B or C. 6)Pregnant patiients. 7)Patients with iodine hypersensitivity. 8)Patients who were estimated that study entry is inappropriate by the responsible physician.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method overall survival rate
- Secondary Outcome Measures
Name Time Method progression-free survival response rate